Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Amsterdam, Netherlands
- Research Site
-
Apeldoorn, Netherlands
- Research Site
-
Den Haag, Netherlands
- Research Site
-
Groningen, Netherlands
- Research Site
-
Helmond, Netherlands
- Research Site
-
Hengelo, Netherlands
- Research Site
-
Hoofddorp, Netherlands
- Research Site
-
Leiden, Netherlands
- Research Site
-
Veldhoven, Netherlands
- Research Site
-
Venlo, Netherlands
- Research Site
-
Zutphen, Netherlands
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participation in the gefitinib Expanded Access Program
- Patient still uses gefitinib in September 2009
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The following characteristics of the 'long-term responders' from the EAP; gender, ethnicity, smoking history (pack years), EGFR-TK mutation and histology of NSCLC.
Time Frame: Characteristics will be recorded once, retrospectively
|
Characteristics will be recorded once, retrospectively
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To assess the long-term safety in subjects treated with gefitinib by collecting information on: All adverse events that have lead to an interruption/reduction of gefitinib or another intervention
Time Frame: Once, retrospectively for the period the patient has used gefitinib (minimal 3 years)
|
Once, retrospectively for the period the patient has used gefitinib (minimal 3 years)
|
|
long-term safety in subjects; what real life data measures are being taken by lung physicians to counter side effects caused by long term gefitinib treatment; the number, reason, effect and description of interventions that have been taken
Time Frame: Once, retrospectively for the period the patient has used gefitinib (minimal 3 years)
|
Once, retrospectively for the period the patient has used gefitinib (minimal 3 years)
|
|
long-term safety: Number, reason and effect of interruptions during gefitinib use to determine side effects typical for the long-term treatment with gefitinib
Time Frame: Once, retrospectively for the period the patient has used gefitinib (minimal 3 years)
|
Once, retrospectively for the period the patient has used gefitinib (minimal 3 years)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NIS-ONL-IRE-2009/1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.